News

RHS Releases Validation Data for NGS Product PG-Seq™

Oct 17, 2017 - latest news

RHS completes extensive validation of its Next Generation Sequencing product PG-Seq™ PG-Seq™ enters clinical validation at external sites ahead of full commercial product launch Adelaide, 17 October 2017: RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to release the performance data for PG-Seq™, its complete Next Generation Sequencing solution for Pre-implantation Genetic Testing, at the Fertility Society of Australia meeting currently being held in Adelaide, South Australia.

Read More

2017 RHS AGM Results and Presentations

May 29, 2017 - latest news

The results of the 2017 RHS AGM held on Friday 26th May 2017 are now available for review.

Read More

RHS Presentations at International Conference on Preimplantation Genetic Diagnosis, Valencia

Mar 30, 2017 - latest news

RHS is pleased to announce that it has been selected to present at the 16th International Conference on Preimplantation Genetic Diagnosis, organized by the Preimplantation Genetic Diagnosis International Society in Valencia. Company CSO Dr Melinda Jasper delivered two oral presentations on Wednesday, 29h of March 2017.

Read More

RHS Presentation at Biotech Showcase, San Francisco

Jan 11, 2017 - latest news

RHS is pleased to announce that it has been selected to present at 9th Annual Biotech Showcase in San Francisco. Non-Executive Chairman Dr David Brookes will deliver a 30 minutes presentation at 2.30 PM on Wednesday, 11th of January 2017.

Read More

Placement and a fully underwritten non-renounceable rights issue raising A$1.5m

Sep 05, 2016 - latest news

On Monday, 5th September 2016 Reproductive Health Science Ltd (“RHS or the “Company”) announced a placement of 7,000,000 shares at $0.075 per share, through Taylor Collison Limited, to sophisticated investors raising $525,000 before costs ("Placement") and a fully underwritten one (1) for five (5) non‐renounceable rights issue to raise approximately A$990,000 (before expenses) (“Rights Issue”).

Read More

DOPlify™ Launch Presentation 23rd August 2016

Aug 25, 2016 - latest news

Dr Melinda Jasper, Chief Scientific Officer, Reproductive Health Science gave a presentation at the DOPlify™ Launch event held on Tuesday, 23rd August 2016

Read More

DOPlify™ Investor Presentation

Aug 25, 2016 - latest news

The investor presentation on the latest product from Reproductive Health Science (ASX:RHS), DOPlify™ , has just been released on the ASX today, 25th August 2016

Read More

Adelaide biotech company Reproductive Health Science Ltd to launch latest product to global market

Aug 17, 2016 - latest news

Adelaide, August 2016: Publicly listed Adelaide biotech company Reproductive Health Science Ltd (ASX:RHS) is launching its second product, DOPlify™ onto the global market.

Read More

Fertility hopes for RHS tests

Apr 12, 2016 - latest news

ADELAIDE listed company Reproductive Health Science is celebrating early success through its collaboration with local in vitro fertilisation (IVF) specialist flindersfertility. (The Advertiser)

Read More